REGENERON PHARMACEUTICALS, INC. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account
REGENERON PHARMACEUTICALS, INC. (REGN) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account of $3.29 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for the quarter ending 2019-12-31 was $203.60M, a 51.26% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for the quarter ending 2019-09-30 was $191.90M, a 54.01% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for the quarter ending 2019-06-30 was $184.90M, a 70.73% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for the quarter ending 2019-03-31 was $147.50M, a 32.41% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2025 was $3.29B, a 7.84% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2024 was $3.05B, a 14.39% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2023 was $2.67B, a 26.52% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to other account for fiscal 2022 was $2.11B, a 35.13% increase from fiscal 2021.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 3 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 3 month as first filed | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 6 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 6 month as first filed | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 9 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 9 month as first filed | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 12 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $3.29B 10-K · filed 2026-02-04 | |||||||
| 2024-12-31 | $3.05B 10-K · filed 2026-02-04 | |||||||
| 2023-12-31 | $2.67B 10-K · filed 2026-02-04 | |||||||
| 2022-12-31 | $2.11B 10-K · filed 2025-02-05 | |||||||
| 2021-12-31 | $1.56B 10-K · filed 2024-02-05 | |||||||
| 2020-12-31 | $1.14B 10-K · filed 2023-02-06 | |||||||
| 2019-12-31 | $203.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $395.50M derived: sum of 2 quarters · filed 2022-02-07 | $580.40M derived: sum of 3 quarters · filed 2022-02-07 | $727.90M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $191.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $376.80M derived: sum of 2 quarters · filed 2019-11-05 | $524.30M 10-Q · filed 2019-11-05 | $658.90M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | $184.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $332.40M 10-Q · filed 2019-08-06 | $467.00M derived: sum of 3 quarters · filed 2021-02-08 | $591.60M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $147.50M 10-Q · filed 2019-05-07 | $282.10M derived: sum of 2 quarters · filed 2021-02-08 | $406.70M derived: sum of 3 quarters · filed 2021-02-08 | $515.00M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | $134.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $259.20M derived: sum of 2 quarters · filed 2021-02-08 | $367.50M derived: sum of 3 quarters · filed 2021-02-08 | $478.90M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $124.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $232.90M derived: sum of 2 quarters · filed 2019-11-05 | $344.30M 10-Q · filed 2019-11-05 | $344.31M 10-Q · filed 2018-11-06 | $456.62M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | $108.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $219.70M 10-Q · filed 2019-08-06 | $219.72M 10-Q · filed 2018-08-02 | $332.02M derived: sum of 3 quarters · filed 2020-02-07 | $439.14M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $111.40M 10-Q · filed 2019-05-07 | $111.38M 10-Q · filed 2018-05-03 | $223.72M derived: sum of 2 quarters · filed 2020-02-07 | $330.84M derived: sum of 3 quarters · filed 2020-02-07 | $430.10M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | $112.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $219.44M derived: sum of 2 quarters · filed 2020-02-07 | $318.70M derived: sum of 3 quarters · filed 2020-02-07 | $408.30M 10-K · filed 2020-02-07 | $408.27M 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $107.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $206.37M derived: sum of 2 quarters · filed 2018-11-06 | $295.98M 10-Q · filed 2018-11-06 | $374.10M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $99.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $188.86M 10-Q · filed 2018-08-02 | $266.98M derived: sum of 3 quarters · filed 2019-02-07 | $339.10M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $89.60M 10-Q · filed 2018-05-03 | $167.73M derived: sum of 2 quarters · filed 2019-02-07 | $239.85M derived: sum of 3 quarters · filed 2019-02-07 | $310.22M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $78.12M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $150.24M derived: sum of 2 quarters · filed 2019-02-07 | $220.62M derived: sum of 3 quarters · filed 2019-02-07 | $278.20M 10-K · filed 2019-02-07 | $278.30M 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $72.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $142.49M derived: sum of 2 quarters · filed 2017-11-08 | $200.08M 10-Q · filed 2017-11-08 | $257.90M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $70.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $127.96M 10-Q · filed 2017-08-03 | $185.78M derived: sum of 3 quarters · filed 2018-02-08 | $237.46M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $57.58M 10-Q · filed 2017-05-04 | $115.41M derived: sum of 2 quarters · filed 2018-02-08 | $167.09M derived: sum of 3 quarters · filed 2018-02-08 | $213.26M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $57.83M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $109.51M derived: sum of 2 quarters · filed 2018-02-08 | $155.67M derived: sum of 3 quarters · filed 2018-02-08 | $193.19M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $51.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $97.85M derived: sum of 2 quarters · filed 2016-11-04 | $135.36M 10-Q · filed 2016-11-04 | $169.06M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $46.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $83.68M 10-Q · filed 2016-08-04 | $117.38M derived: sum of 3 quarters · filed 2017-02-09 | $143.70M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $37.52M 10-Q · filed 2016-05-05 | $71.22M derived: sum of 2 quarters · filed 2017-02-09 | $97.53M derived: sum of 3 quarters · filed 2017-02-09 | $125.18M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2014-12-31 | $33.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $60.01M derived: sum of 2 quarters · filed 2017-02-09 | $87.66M derived: sum of 3 quarters · filed 2017-02-09 | $111.86M 10-K · filed 2017-02-09 | ||||
| 2014-09-30 | $26.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $53.96M derived: sum of 2 quarters · filed 2015-11-04 | $78.16M 10-Q · filed 2015-11-04 | $102.50M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | $27.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $51.84M 10-Q · filed 2015-08-04 | $76.19M derived: sum of 3 quarters · filed 2016-02-11 | $100.67M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | $24.19M 10-Q · filed 2015-05-07 | $48.54M derived: sum of 2 quarters · filed 2016-02-11 | $73.03M derived: sum of 3 quarters · filed 2016-02-11 | $94.41M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $24.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $48.83M derived: sum of 2 quarters · filed 2016-02-11 | $70.21M derived: sum of 3 quarters · filed 2016-02-11 | $89.88M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | $24.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $45.87M derived: sum of 2 quarters · filed 2013-11-05 | $65.53M 10-Q · filed 2013-11-05 | $83.31M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | $21.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $41.04M 10-Q · filed 2013-08-06 | $58.82M derived: sum of 3 quarters · filed 2015-02-12 | $76.82M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $19.66M 10-Q · filed 2013-05-03 | $37.44M derived: sum of 2 quarters · filed 2015-02-12 | $55.44M derived: sum of 3 quarters · filed 2015-02-12 | $71.80M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | $17.78M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $35.77M derived: sum of 2 quarters · filed 2015-02-12 | $52.14M derived: sum of 3 quarters · filed 2015-02-12 | $62.25M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | $18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $34.36M derived: sum of 2 quarters · filed 2012-10-24 | $44.47M 10-Q · filed 2012-10-24 | |||||
| 2012-06-30 | $16.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $26.48M 10-Q · filed 2012-07-25 | ||||||
| 2012-03-31 | $10.11M 10-Q · filed 2012-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |